Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.

Oncotarget · 2016 · PMC5312402 · PMID 27528035

Europe PMC DOI

hedged sentence

0.0930

closest p · 1.9× alpha

0.0930

boldest claim

The sentences

showed a trendP =0.093so close (0.05 < p ≤ 0.1)

Rs734693 CT/TT genotypes showed a trend of lower GR ratio ( P =0.093, dominant model) with an OR of 1.50 (95% CI: 0.93-2.41).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.